Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells

Molecular Pharmacology

Volumn 70, Issue 6, 2006, Pages 1844-1849

  Benyó, Zoltán ^a,c   Gille, Andreas ^a   Bennett, Clare L ^b   Clausen, Björn E ^b   Offermanns, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; NICOTINIC ACID; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTANOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL ACTIVATION; CELL ACTIVITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG ACTIVITY; EPIDERMIS CELL; FLUSHING; LANGERHANS CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL SEPARATION; FLOW CYTOMETRY; FLUORESCENCE; FLUSHING; LANGERHANS CELLS; MICE; NIACIN; SKIN;

EID: 33751087034     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.030833     Document Type: Article

References (36)

1. Andersson RG, Aberg G, Brattsand R, Ericsson E, and Lundholm L (1977) Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh) 41:1-10.
2. Bennett CL, van Rijn E, Jung S, Inaba K, Steinman RM, Kapsenberg ML, and Clausen BE (2005) Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 169:569-576.
3. Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM, Moers A, Pfeffer K, and Offermanns S (2005) GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Investig 115:3634-3640.
4. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592.
5. Carlson LA (2005) Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258:94-114.
6. Carlson LA (2006) Nicotinic acid and other therapies for raising high-density lipoprotein. Curr Opin Cardiol 21:336-344.
7. Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, et al. (2006) Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 103:6682-6687.
8. Coronary Drug Project Research Group (1975) Clofibrate and niacin in coronary heart disease. J Am Med Assoc 231:360-381.
9. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, and Iredale JP (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Investig 115:56-65.
10. Dupasquier M, Stoitzner P, van Oudenaren A, Romani N, and Leenen PJ (2004) Macrophages and dendritic cells constitute a major subpopulation of cells in the mouse dermis. J Investig Dermatol 123:876-879.
11. Eklund B, Kaijser L, Nowak J, and Wennmalm A (1979) Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 17:821-830.
12. English JS, Winkelmann RK, Louback JB, Greaves MW, and MacDonald DM (1987) The cellular inflammatory response in nicotinate skin reactions. Br J Dermatol 116:341-349.
13. Exton JH (1996) Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Annu Rev Pharmacol Toxicol 36:481-509.
14. Goldsmith GA and Cordill S (1943) The vasodilating effects of nicotinic acid (relation to metabolic rate and body temperature). Am J Med Sci 205:204-208.
15. + T cells by exogenous cell-associated antigens. Immunity 17:211-220.
16. Kaijser L, Eklund B, Olsson AG, and Carlson LA (1979) Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 57:114-117.
17. Kontush A and Chapman MJ (2006) Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3:144-153.
18. Kudo I and Murakami M (2005) Prostaglandin e synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol 38:633-638.
19. Lenz A, Heine M, Schuler G, and Romani N (1993) Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Investig 92:2587-2596.
20. Leung DY, Boguniewicz M, Howell MD, Nomura I, and Hamid QA (2004) New insights into atopic dermatitis. J Clin Investig 113:651-657.
21. Morrow JD, Awad JA, Oates JA, and Roberts LJ 2nd (1992) Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Investig Dermatol 98:812-815.
22. Morrow JD, Parsons WG 3rd, and Roberts LJ 2nd (1989) Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38:263-274.
23. Nozaki S, Kihara S, Kubo M, Kameda K, Matsuzawa Y, and Tarui S (1987) Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. Int J Clin Pharmacol Ther Toxicol 25:643-647.
24. Offermanns S (2006) The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 27:384-390.
25. Olsson AG (1994) Nicotinic acid and derivatives, in Principles and Treatment of Lipoprotein Disorders (Schettler G and Habenicht AJR eds) pp 349-400, Springer Verlag, New York.
26. Rhee SG (2001) Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70:281-312.
27. Rosenbach T, Czernielewski J, Hecker M, and Czarnetzki B (1990) Comparison of eicosanoid generation by highly purified human Langerhans cells and keratinocytes. J Investig Dermatol 95:104-107.
28. Ruzicka T and Aubock J (1987) Arachidonic acid metabolism in guinea pig Langerhans cells: studies on cyclooxygenase and lipoxygenase pathways. J Immunol 138:539-543.
29. Schaub A, Futterer A, and Pfeffer K (2001) PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol 31:3714-3725.
30. Spies TD, Cooper C, and Blankenhorn MA (1938) The use of nicotinic acid in the treatment of pellagra. J Am Med Assoc 110:622-627.
31. Stern RH, Spence JD, Freeman DJ, and Parbtani A (1991) Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 50:66-70.
32. Svedmyr N, Heggelund A, and Aberg G (1977) Influence of indomethacin on flush induced by nicotinic acid in man. Acta Pharmacol Toxicol (Copenh) 41:397-400.
33. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, and Grace KA (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110:3512-3517.
34. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, and Offermanns S (2003) PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9:352-355.
35. Uehara M and Ofuji S (1977) Abnormal vascular reactions in atopic dermatitis. Arch Dermatol 113:627-629.
36. Wilkin JK, Fortner G, Reinhardt LA, Flowers OV, Kilpatrick SJ, and Streeter WC (1985) Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther 38:273-277.